RADX doses first patient in second Phase 1/2a BetaBart cohort
Radiopharm Theranostics (RADX) dosed the first patient in the second cohort of its Phase 1/2a trial of BetaBart (RV-01) in B7-H3 expressing solid tumors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.